Harmony Biosciences Holdings (HRMY) Capital Expenditures (2019 - 2025)
Harmony Biosciences Holdings (HRMY) reported Capital Expenditures of $107000.0 for Q4 2025, down 79.14% on a YoY basis from $513000.0 in Q4 2024, and up 50.7% sequentially from $71000.0 in Q3 2025.
Harmony Biosciences Holdings (HRMY) Capital Expenditures (2019 - 2025) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 7 years of Capital Expenditures data on file, last reported at $107000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 79.14% year-over-year to $107000.0; the trailing twelve-month figure through Dec 2025 stood at $310000.0 (down 73.11% YoY), and the FY2025 full-year result was $310000.0, down 73.11% from the prior year.
- Capital Expenditures grew to $107000.0 in Q4 2025, from $71000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $632000.0 in Q2 2024 to a low of $3000.0 in Q3 2024.
- A 5-year average of $136000.0 and a median of $86000.0 in 2022 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 2460.0% in 2025, while the deepest fall reached 99.37% in 2025.
- Tracing HRMY's Capital Expenditures over 5 years: stood at $93000.0 in 2021, then slipped by 7.53% to $86000.0 in 2022, then advanced by 24.42% to $107000.0 in 2023, then surged by 379.44% to $513000.0 in 2024, then plunged by 79.14% to $107000.0 in 2025.
- Business Quant data shows HRMY's Capital Expenditures at $107000.0 in Q4 2025, $71000.0 in Q3 2025, and $4000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | Harmony Biosciences Holdings | 2.09 Bn | 1.57 Bn | 170.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 107,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Sep 30, 2025 | 71,000.00 |
| Sep 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Dec 31, 2024 | 513,000.00 |
| Dec 31, 2024 | 513,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 632,000.00 |
| Jun 30, 2024 | 632,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2022 | 86,000.00 |
| Sep 30, 2022 | 86,000.00 |